中恒集团：关于控股孙公司获得药物临床试验批准通知书的公告

Group 1 - The core point of the article is that Zhongheng Group announced the approval of a clinical trial for an innovative anti-cancer drug, "Nano Carbon Iron Suspension Injection," by the National Medical Products Administration of China [2] - The drug is developed by Sichuan Yingrui Pharmaceutical Technology Co., Ltd., a subsidiary of Chongqing Laimei Pharmaceutical Co., Ltd., which is a holding subsidiary of Zhongheng Group [2] - The clinical trial will investigate the combination of Nano Carbon Iron with standard radiotherapy in patients with solid tumors [2]